Form 4: Avanos Medical Director Receives Restricted Share Units

Avanos Medical, Inc. reports that Director Patrick J. O'Leary was issued 12,003 restricted share units on May 8, 2026, replacing prior units.

Summary

• Patrick J. O'Leary, a Director at Avanos Medical, Inc., was granted 12,003 restricted share units (RSUs) on May 8, 2026.
• These RSUs represent a contingent right to receive a cash payment equivalent to the value of one share of Avanos Medical's common stock.
• The issuance of these RSUs replaces previously issued restricted share units granted on January 2, 2025.
• The RSUs will vest upon the reporting person's termination of service on the Issuer's Board of Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation adjustment for a director rather than a significant strategic or financial event.

Positives

• Director compensation through equity awards like RSUs can align management interests with shareholder value.
• The replacement of existing RSUs suggests a continuation of incentive structures for key personnel.

Negatives

• The filing does not provide details on the specific valuation or vesting schedule beyond termination of service, which could be a point of interest for shareholders.

Risks

• The value of the restricted share units is tied to the future performance and stock price of Avanos Medical, Inc., introducing market risk.
• Vesting is contingent on the director's continued service, implying a potential loss of these units if service is terminated prematurely.

Future Outlook

The future outlook for the restricted share units is dependent on the vesting conditions being met (termination of service) and the future stock price performance of Avanos Medical, Inc.

Industry Context

StockSavvy.ai notes that the issuance of restricted share units to directors is a common practice in the healthcare and medical technology sector to attract, retain, and incentivize experienced leadership aligned with long-term company performance.

Stakeholder Impact

• Shareholders: The issuance of RSUs is a form of compensation, which impacts dilution and executive compensation costs. The alignment of director incentives with stock performance is generally viewed positively.
• Employees: Indirectly, the retention of experienced directors can contribute to stable leadership and strategic direction, benefiting the overall company and its employees.
• Management: The reporting person, Patrick J. O'Leary, benefits from this equity award as part of his compensation package.

Next Steps

• The restricted share units will vest upon the reporting person's termination of service on the Issuer's Board of Directors.
• The cash payment upon vesting will be equal to the value of one share of Avanos Medical's common stock at that time.

Key Dates

Keywords

Avanos Medical, Form 4, SEC Filing, Restricted Share Units, Director Compensation, Equity Awards, Beneficial Ownership, Patrick J. O'Leary, AVNS